Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
PT-141 reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
PT-141 is a synthetic alpha-melanocyte-stimulating hormone analogue, heptapeptide of 7 amino acids. Based on alpha-melanocyte-stimulating hormone (alpha-MSH).
Reported to activate central nervous system melanocortin receptors MC3R and MC4R. Its reported site of action is central, not vascular — which is what distinguishes it from PDE5 inhibitors. Vectra makes no claim as to mechanism or effect.
An FDA-approved product containing this moiety exists, approved 2019 for one indication in one population under its own labelling. A research-use reference material is not that product.
Originally developed by Palatin Technologies, evaluated in Phase 3 trials for hypoactive sexual desire disorder in premenopausal women, and approved by FDA in 2019. First described by Palatin Technologies.
Studied in melanocortin receptor signalling. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
Approved for one indication in one population on Phase 3 evidence. Off-label use in men is reported but is not what the approval covers.
Our sources carry no CAS number, formula, molecular weight, sequence, safety data, or storage data for PT-141.
An approved product containing this moiety exists (2019). This material is supplied for in-vitro research use only. No therapeutic, preventive, or diagnostic claims are made or implied.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.